Introduction
============

Histamine is a neurotransmitter present in both the peripheral and central nervous systems that is involved in the modulation of anxiety-related behavior in animals. Furthermore, it has been implicated in cognitive functions, including learning and memory ([@B01], [@B02]). The functions of histamine are mediated through different receptor subtypes: H~1~, H~2~, H~3~, and H~4~ ([@B03], [@B04]).

It has been suggested that the histaminergic system may exert tonic modulatory control over emotional behavior ([@B05]). In addition, some evidence supports the concept that histaminergic neurons influence anxiety-related behavior via H~1~ and H~2~ receptor activation ([@B06], [@B07]). For example, administration of the H~1~ receptor antagonist pyrilamine or H~2~ receptor antagonist ranitidine in the dorsal hippocampus was found to induce anxiogenic-like behavior in mice in a hole-board test ([@B07]). Furthermore, evidence has demonstrated that histamine can facilitate long-term potentiation by activating histamine receptor subtypes (H~1~ and H~2~) and consequently modulates synaptic plasticity ([@B02], [@B08]). It is accepted that synaptic plasticity is the cellular basis of emotional memory because long-term potentiation is correlated with memory trace formation ([@B02]). Studies have also investigated the effects of H~1~ and H~2~ histaminergic receptor activation on emotional memory in animals ([@B09], [@B10]) and humans ([@B11]).

The elevated plus-maze (EPM) is a widely used test for animal anxiety ([@B12], [@B13]) and according to Galvis-Alonso et al. ([@B14]), animals acquire information about safe and dangerous areas of the maze during EPM testing. Repeated testing provides a measure of the acquisition and retention of memories because experience-dependent behavioral changes can be observed. Our laboratory has performed studies on the histaminergic system addressing anxiety and emotional memory in mice using a Trial 1/Trial 2 (T1/T2) protocol in an EPM ([@B15], [@B16]). Although these studies have indicated that histamine H~1~ receptors could have a modulatory effect on memory processes, few studies have investigated the effects of histamine mediated by H~2~ receptors on emotional behavior using repeated testing in an EPM.

Therefore, the objective of the present study was to investigate the effects of a systemically administered selective histamine H~2~ receptor antagonist, zolantidine (ZOL) and a histamine H~1~ receptor antagonist, chlorpheniramine (CPA), on the modulation of anxiety-related behaviors and the retrieval and acquisition of emotional memory in mice re-exposed to EPM testing.

Subjects and Methods
====================

Subjects
--------

The experimental subjects were adult male Swiss albino mice supplied by the Animal Facility of Universidade Federal de São Carlos, São Carlos, SP, Brazil, weighing 30-35 g at testing. The mice were housed in groups of 10 per cage (41 x 34 x 16 cm) and maintained under a 12-h light cycle (light on at 7:00 am) in a controlled environment with a temperature of 23 ± 1°C and a relative humidity of 50 ± 5%. The experimental sessions were conducted during the light period of the cycle (9:00 am and 4:00 pm). Food and drinking water were provided *ad libitum*, except during the brief testing periods. All mice were experimentally naive at the beginning of the study.

Drugs
-----

Zolantidine (an H~2~ receptor antagonist; Sigma, USA) and chlorpheniramine maleate salt (an H~1~ receptor antagonist; Sigma) were dissolved in sterile 0.9% saline. The drugs were injected intraperitoneally (*ip*) at a volume of 2 mL/kg body weight, and the final dose was 20 mg/kg ZOL and 8.0 or 16 mg/kg CPA. The applied doses were based on previous studies ([@B06], [@B15], [@B17]) and on pilot work performed in our laboratory.

Saline (SAL) was used as control. Both drugs (ZOL and CPA), and SAL were placed in coded Eppendorf tubes under refrigeration. This coding was unknown to the experimenter at the time of the behavioral analysis testing.

Apparatus
---------

The apparatus used for EPM testing was similar to those previously developed and validated for rats ([@B12]) and for mice ([@B13]). It was constructed from wood, and its enclosed arms had transparent glass walls. The maze consisted of four arms: two open (30 x 5 x 0.25 cm) and two enclosed arms (30 x 15 x 5 cm) extending from a common central platform (5 x 5 cm) and was elevated to a height of 38.5 cm from the floor. All tests were conducted under moderate illumination (77 lx, measured on the central platform of the EPM) during the light phase of the diurnal cycle.

Experimental procedure
----------------------

On the day of the experiment, to facilitate adaptation, animals were transported to a dimly lit room and left undisturbed for at least 1 h before testing to facilitate adaptation. The experiments were performed on two consecutive days, designated T1 and T2. In T1, the mice received an *ip* injection of SAL, ZOL, and 8 or 16 mg/kg CPA. For each drug tested there was a corresponding control group in T1, resulting in the following paired groups: SAL (n = 20) and ZOL (n = 21), SAL (n = 20) and 8 mg/kg CPA (n = 20), and SAL (n = 20) and 16 mg/kg CPA (n = 22). Forty minutes after the injections ([@B06], [@B18]), the mice were exposed to the EPM (T1). In T2 (24 h later), each group was subdivided into two new groups, and the animals from each group were re-injected with SAL or one of the drugs prior to conducting T2. For each drug administered, the animals were randomly assigned to four groups based on the drug treatment: 20 mg/kg ZOL: SAL-SAL (n = 11), SAL-ZOL (n = 9), ZOL-SAL (n = 10), ZOL-ZOL (n = 11); 8 mg/kg CPA: SAL-SAL (n = 13), SAL-CPA (n = 10), CPA-SAL (n = 8), CPA-CPA (n = 9), and 16 mg/kg CPA: SAL-SAL (n = 12), SAL-CPA (n = 10), CPA-SAL (n = 10), CPA-CPA (n = 10).

Each testing session began by placing the subject on the central platform of the maze facing an open arm. The subject was allowed 5 min of free exploration. Between animals, the maze was thoroughly cleaned with 20% alcohol and dry cloths. All sessions were video recorded using a camera positioned above and at a 50° angle with respect to the maze to permit the discrimination and documentation of all behaviors. The video signal was also relayed to a monitor for real-time observation in another room.

Behavioral analysis
-------------------

Videotapes were scored by a highly trained observer using the ethological analysis software package X-Plot-Rat developed at Laboratório de Comportamento Exploratório, USP, Ribeirão Preto ([@B19]). The conventional measures recorded were the frequency of closed arm entries (arm entry = all four paws into an arm), percentage of open arm entries \[%OAE = (open / total) x 100\] and percentage of time spent (%OAT) in open parts of the maze \[(time open / 300) x 100\].

Statistical analysis
--------------------

Initially, all results were subjected to the Levene test for homogeneity of variance. When appropriate, the data were square-root transformed and then analyzed by the Student *t*-test (T1) or two-way repeated measures ANOVA (T2; factor 1: treatment; factor 2: trial). Significant *F* tests were followed by *post hoc* Fisher LSD tests (protected *t*-tests). In all cases, P values less than 0.05 were considered to be significant.

Ethics
------

All procedures were approved by the Ethics Committee on Animal Experimentation of Universidade Federal de São Carlos (028/2007) and were consistent with the recommendations of the Brazilian Society of Neuroscience and Behavior (SBNeC), which are based on the US National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Results
=======

Effects of *ip* injection of SAL or 20 mg/kg ZOL on anxiety and emotional memory retrieval
------------------------------------------------------------------------------------------

[Table 1](#t01){ref-type="table"} shows the effects of *ip* SAL or 20 mg/kg ZOL injections on EPM behavioral measures. The Student *t*-test detected no difference between the SAL and ZOL groups in %OAE (t~(20)~ = 0.53, P \> 0.05) or %OAT (t~(20)~ = 0.16, P \> 0.05), suggesting that ZOL has no effect on anxiety. Furthermore, no difference was observed in enclosed arm entry (EAE; t~(20)~ = 0.10, P \> 0.05) ([Table 2](#t02){ref-type="table"}) in T1, and the Student *t*-test showed no differences for the SAL and ZOL groups, indicating that there was no alteration in locomotor activity.

As indicated in [Table 3](#t03){ref-type="table"}, ANOVA confirmed the effects of the trial factor on %OAE (F~(1,40)~ = 26.3, P \< 0.05) and %OAT (F~(1,40)~ = 27.3, P \< 0.05). The Fisher LSD test showed that there was decreased open arm activity in T2 in the SAL-SAL, SAL-ZOL, ZOL-SAL, and ZOL-ZOL groups, indicating that ZOL did not affect emotional memory retrieval.

Effects of *ip* injection of SAL or CPA (8 mg/kg) on anxiety and emotional memory retrieval
-------------------------------------------------------------------------------------------

The effects of *ip* injection of SAL or CPA at a dose of 8.0 mg/kg on EPM behavioral measures are shown in [Table 1](#t01){ref-type="table"}. The Student *t*-test revealed no significant differences between the SAL and CPA groups for %OAE (t~(20)~ = 1.71, P \> 0.05) or %OAT (t~(20)~ = 0.53, P \> 0.05) in T1, suggesting that CPA at this dose has no effect on anxiety. Concerning EAE, the Student *t*-test showed no differences for the SAL and CPA groups, indicating that there was no alteration in locomotor activity ([Table 2](#t02){ref-type="table"}).

For T2, ANOVA confirmed a statistically significant effect of the trial on %OAE (F~(1,39)~ = 46.39, P \< 0.05) and %OAT (F~(1,39)~ = 28.12, P \< 0.05). The Fisher LSD test showed decreased open arm exploration (%OAE and %OAT) for all experimental groups ([Table 3](#t03){ref-type="table"}).

Effects of *ip* injection of SAL or 16 mg/kg CPA on anxiety and emotional memory retrieval
------------------------------------------------------------------------------------------

[Figure 1A,B](#f01){ref-type="fig"} shows the effects of *ip* injection of SAL or CPA at a dose of 16 mg/kg on EPM behavioral measures. The Student *t*-test revealed a significant decrease in %OAE (t~(20)~ = 3.74, P \< 0.05) and %OAT (t~(20)~ = 2.43, P \< 0.05) for the CPA group compared to the SAL group. These results indicate that the highest dose of CPA (16 mg/kg) induced anxiogenic-like effects in mice. The Student *t*-test detected no differences between the SAL and CPA groups for EAE (t~(20)~ = 1.30, P \> 0.05) in T1 ([Table 2](#t02){ref-type="table"}), indicating that the highest dose of CPA did not affect locomotor activity.

![Effects of *ip* injection of chlorpheniramine (CPA; n = 22) on the percentage of open arm entries (%OAE; *A*) and the percentage of time spent in the open arms (%OAT; *B*) during Trial 1 (T1). CPA (16 mg/kg, *ip*) or saline (SAL) was administered prior to T1. Data are reported as means ± SE. \*P \< 0.05 for the differences between the SAL and CPA groups in T1 (Student *t*-test).](1414-431X-bjmbr-00-00-20132770-gf01){#f01}

[Table 3](#t03){ref-type="table"} presents a comparison between T1 and T2, and repeated measures ANOVA revealed a significant effect of the trials on %OAE (F~(1,41)~ = 21.91, P \< 0.05) and %OAT (F~(1,41)~ = 32.53, P \< 0.05). The *post hoc* test indicated a reduction in both variables for the SAL-SAL and SAL-CPA groups, but not for the CPA-SAL and CPA-CPA groups in T2 (ANOVA, P \> 0.05).

Discussion
==========

The main results of this study show that systemic administration of 8 mg/kg CPA and 20 mg/kg ZOL did not affect behavioral measures of anxiety. Treatment with CPA at the highest dose induced anxiety-related behavior in mice subjected to the EPM. Importantly, no significant changes were observed in the number of EAE in T1, a parameter considered to be a valid measure of locomotor activity in EPM tests ([@B20]).

Our results show that the injection of ZOL or 8 mg/kg CPA *ip* prior to T1 did not affect anxiety because no significant difference in open arm activity (%OAE and %OAT) was observed between the SAL and ZOL or CPA groups during T1. Our results are consistent with previous studies conducted in our laboratory, which have demonstrated that *ip* injection of 8 mg/kg CPA and intra-amygdala infusions of CPA (0.016 and 0.052 nmol/0.1 µL) do not alter anxiety levels in mice exposed to the EPM ([@B15], [@B16]). In another study, treatment with 20 mg/kg *ip* ZOL, an H~2~ receptor antagonist, also did not affect anxiety in mice subjected to the EPM ([@B06]). In the present study, administration of CPA at the highest dose (16 mg/kg) decreased %OAT and %OAE, which are parameters associated with anxiety-related behavior, without locomotor impairment in the EPM, indicating an anxiogenic response, which is in agreement with the data obtained in previous studies ([@B06], [@B21]). It has been proposed that histamine modulates the release of acetylcholine via stimulation of H~1~ receptors. For example, superfusion with an H~1~ receptor antagonist was found to decrease the release of acetylcholine in the rat ventral striatum ([@B22]). Since acetylcholine may modulate anxiety-related behaviors ([@B23]), one may expect that this response of the highest doses of antagonist CPA is mediated through changes in acetylcholine levels, but this hypothesis has not yet been tested. In contrast, other studies have reported an anxiolytic response mediated by H~1~ receptors in rats and mice ([@B24], [@B25]). The reported discrepancies could be related to experimental differences among the many factors that appear to influence the aversion to open arms, such as the time of day at which testing occurs [@B26] and the levels of illumination in the testing room ([@B27]).

We detected a notable decrease in open arm activity (%OAE and %OAT) in the animals treated with ZOL and CPA at a dose of 8 mg/kg during T2. Our results indicate that learning occurred in these groups during T1 and that emotional memory was evoked in T2, which corroborates the findings of previous studies performed in our laboratory indicating that CPA does not affect emotional memory in mice ([@B15], [@B16]). Behavioral studies have indicated that H~1~ and H~2~ receptors enhance the processes of learning and memory in rats ([@B24], [@B28]). Another study has suggested that neither H~1~ nor H~2~ receptors alter lithium state-dependent retrieval of memory in mice when administered as pre-test treatment ([@B29]). In our study, the animals that received CPA at the highest dose did not show altered activity in the open arms upon a second exposure to the EPM, indicating an emotional memory acquisition and consolidation deficits. These results could primarily be explained by the anxiety responses observed in the group that received 16 mg/kg CPA prior to the first exposure to the EPM, impairing the normal acquisition of configural and contextual characteristics of the maze and inducing the performance impairment observed in the T2 session. However, the anxiety-related behaviors induced by this drug in the EPM are associated with a normal and adaptive anxiety range and it is unlikely that the memory impairment is due to this anxiety. A recent study investigating the relationship between anxiety and cognitive functions found no short-memory or long-memory impairment in mouse strains that display adaptive anxiety ([@B30]). Our results agree with other studies showing that administration of CPA impairs learning and memory processes ([@B31], [@B32]). A recent study conducted in our laboratory demonstrated that infusion of CPA (0.16 nmol/0.1 µL) in the amygdala induces emotional memory impairment *per se* at the highest dose tested ([@B16]). Furthermore, behavioral evidence has indicated that the regulatory mechanisms of histamine neural circuits affecting learning and memory are possibly related to their dynamic neural network connections with many structures ([@B33]), suggesting tonic modulatory control of this neurotransmitter.

The widespread extension of histaminergic neurons suggests that this system might influence different brain regions; one such area, the locus coeruleus, modulates the attentional state and presents a tight neuromodulatory interaction with the amygdala ([@B34]), which play an important regulatory role in the acquisition of emotionally based learning and memory ([@B35]). An *in vitro* study conducted by Korotkova et al. ([@B36]) demonstrated that histamine excites noradrenergic neurons in the rat locus coeruleus via H~1~ receptors. We suggest that *ip* injection of CPA, an H~1~ histaminergic antagonist, at the highest dose tested, decreased adrenergic neuron activation in this structure, which impaired emotional memory retrieval in mice during a second exposure to the EPM. Our results suggest that the emotional memory impairment induced by chlorpheniramine in rodents is under the tonic modulatory control of histamine.

We conclude that anxiety-like behavior and emotional memory acquisition and consolidation deficits are mediated by H~1~ but not H~2~ receptors in mice re-exposed to EPM testing.
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